GLUE

8.6403.03%
JS

Jan Skvarka

Independent Director

Dr. Jan Skvarka, MBA, is Member of Strategic Advisory Board of Sensible Biotechnologies, Inc. from October 2026. He serves as an Independent Director at Monte Rosa Therapeutics, Inc. from March 2023. He has been an Independent Director of Zentalis Pharmaceuticals, Inc. from September 2022. Dr. Skvarka serves as Executive Chairman of the Board of GentiBio, Inc. from 2022. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc. Dr. Skvarka served as President, Chief Executive Officer and Director of Trillium Therapeutics Inc. since September 25, 2019 until November 17, 2021. Prior to joining Trillium, Dr. Skvarka served as the Chief Executive Officer and President of Tal Medical Inc. from 2014 to 2018. Dr. Skvarka joined Tal Medical in 2014, with the goal of accelerating Tal’s path toward pivotal trials and commercialization. Prior to Tal, Dr. Skvarka spent with Bain & Company, Boston, as a healthcare consultant. In his role, he advised senior executives of medical device and pharmaceutical clients on issues related to strategy, performance improvement and corporate development. He was Partner in the Healthcare practice from 2007 until 2013, with a focus on pharmaceutical, biotechnology and medical technology companies. Prior to Bain, Dr. Skvarka worked with Price Waterhouse Corporate Finance in London and Vienna, focusing on M&A and capital raising. He serves as a Director of Tal Medical Inc. Dr. Skvarka authored multiple publications on healthcare and financing topics and speaks at industry conferences as an expert on life sciences businesses. Dr. Skvarka received an MBA from Harvard Business School, Boston and a BS in business administration and PhD in Economics from University of Economics, Slovakia and is a Certified Accountant in Austria.

Positions